Skip to content
PeptideTech
Cart

Home / Research library / Survodutide

Peptides

Survodutide: molecular data, studies & sources

Survodutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C192H289N47O61
Molecular weight (MW)
4232 g/mol
PubChem compound ID
168429725
Record title
Survodutide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 168429725 · retrieved 2026-09-21

PubChem 2D molecular structure for Survodutide, CID 168429725
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
18-[[4-[[2-[[(2R)-1-[[2-[[(2R)-1-[[2-[[2-[[(5R)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
InChIKey
MEDXQFAHWBMVIM-YIUAJOCSSA-N
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N
Machine-readable PubChem source

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

    Sanyal AJ, Bedossa P, Fraessdorf M et al. · The New England journal of medicine · 2024

    PMID 38847460 · DOI: 10.1056/NEJMoa2401755

  2. Human study · PubMed trial index

    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

    le Roux CW, Steen O, Lucas KJ et al. · The lancet. Diabetes & endocrinology · 2024

    PMID 38330987 · DOI: 10.1016/S2213-8587(23)00356-X

  3. Human study · PubMed trial index

    Survodutide Once Weekly for the Treatment of Adults with Obesity.

    le Roux CW, Wharton S, Startseva E et al. · The New England journal of medicine · 2026

    PMID 42253238 · DOI: 10.1056/NEJMoa2600751

  4. Human study · PubMed trial index

    Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

    Blüher M, Rosenstock J, Hoefler J et al. · Diabetologia · 2024

    PMID 38095657 · DOI: 10.1007/s00125-023-06053-9

  5. Human study · PubMed trial index

    Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

    Lawitz EJ, Fraessdorf M, Neff GW et al. · Journal of hepatology · 2024

    PMID 38857788 · DOI: 10.1016/j.jhep.2024.06.003

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.

    Survodutide supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    Compare all Survodutide sizes, forms and supplier prices →

    SupplierRecorded packagesExample source listing
    Amino USAUSD6mg Vial1 recorded offers6mg Vial · $81.00Checked Sep 16, 2026Supplier listing
    Cenexa LabsUSD10mg Vial1 recorded offers10mg Vial · $118.99Checked Sep 16, 2026Supplier listing

    Reference sources & further reading

    The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

    Search for additional research

    These links run searches; their results have not been individually reviewed and can include unrelated compounds.

    Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

    Related research profiles